International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study.
Phillip R FoxBruce W KeeneKenneth LambKarsten A SchoberValerie ChetboulVirginia Luis FuentesGerhard WessJessie Rose PayneDaniel F HoganAlison Motsinger-ReifJens HäggströmEmilie Trehiou-SechiDeborah M Fine-FerreiraReid K NakamuraPamela Ming-Show LeeManreet K SinghWendy A WareJonathan A AbbottGeoffrey CulshawSabine RiesenMichele BorgarelliMichael B LesserNicole Van IsraëlEtienne CôtéJohn E RushBarret BulmerRoberto A SantilliAndrea C VollmarMaribeth J BossbalyNadine QuickClaudio BussadoriJanice M BrightAmara H EstradaDan G OhadMaria Josefa Fernández-Del PalacioJenifer Lunney BrayleyDenise S SchwartzChristina M BovéSonya G GordonSeung Woo JungPaola BrambillaN Sydney MoïseChristopher D StauthammerRebecca L StepienCecilia QuintavallaChristophe AmbergerFerenc ManczurYong-Wei HungRemo LobettiMarie De SwarteAlice TamboriniCarmel T MooneyMark A OyamaAndrey KomolovYoko FujiiRomain PariautMasami UechiVictoria Yukie Tachika OharaPublished in: Journal of veterinary internal medicine (2018)
Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.